Abstract: Chimeric antigen receptor (CAR)-engineered T-cell therapy is a type of tumor immunotherapy. CAR T-cells recognize target sites on the tumor and are activated to release cytokines and to exert the T-cells' killing effect on tumor cells. It also makes use of costimulatory factors to assist these T-cells in exerting a sustained anti-tumor effect. Hematologic malignancies and neuroblastomas are prevalent among children. However, effective treatment for refractory and recurrent pediatric cancers is currently lacking. CAR T-cell therapy has been found to play an important role in the treatment of tumors that arise preferentially in children and has a good effect on the treatment of refractory and recurrent tumors.